When does HBM Healthcare report earnings and why does it matter for HBMN.SW stock?

HBM Healthcare reports on **23 Jan 2026**. The earnings release can change NAV, reveal realised gains or losses, and affect dividend expectations. For HBMN.SW stock this report is the main near-term price catalyst.

What valuation metrics should investors check for HBMN.SW stock?

Focus on **PE (17.31)**, **book value per share CHF251.31**, and dividend yield **3.17%**. Also compare price-to-book versus peers and monitor NAV changes for HBMN.SW stock.

How does Meyka AI view HBMN.SW stock ahead of earnings?

Meyka AI rates HBMN.SW **69.97 (Grade B, HOLD)** and models a near-term monthly target of **CHF238.04**. This outlook is model-based and not a guaranteed outcome for HBMN.SW stock.

What are realistic trading scenarios for HBMN.SW stock after earnings?

Bull case supports **CHF260.00** to **CHF300.00**, base case holds near current price, and downside could reach **CHF180.00** if NAVs are marked down. These scenarios help size risk for HBMN.SW stock.

CH Stocks

HBMN.SW HBM Healthcare (SIX) CHF237 intraday 19 Jan 2026: earnings due 23 Jan could shift valuation

ByDanny Kontos January 19, 2026January 19, 2026

HBMN.SW stock trades at CHF237.00 intraday on 19 Jan 2026, down -0.84% for the day. The fund reports results on 23 Jan 2026, a near-term catalyst that could move the share price. We review valuation, portfolio exposure, technicals and model forecasts to frame trading scenarios ahead of the earnings release.